A novel UHPLC‒MS/MS method for quantitative analysis of zanubrutinib in rat plasma: application to an in vivo interaction study between zanubrutinib and triazole antifungal

Table 5 The main pharmacokinetic parameters of zanubrutinib in different treatment groups of rats

Parameters	Unit	Group A	Group B	Group C
AUC_(0−t)	µg/L*h	1081.67 ± 43.81	1,267.55 ± 79.35*	1721.61 ± 219.36**
AUC_(0−∞)	µg/L*h	1085.49 ± 44.17	1272.62 ± 77.99*	1729.93 ± 218.06**
MRT_(0−t)	h	2.71 ± 0.10	2.76 ± 0.07	2.95 ± 0.14*
MRT_(0−∞)	h	2.76 ± 0.09	2.82 ± 0.09	3.00 ± 0.14*
t_1/2	h	1.34 ± 0.11	1.42 ± 0.56	1.37 ± 0.16
T_max	h	1.83 ± 0.41	2.00 ± 0.00*	2.17 ± 0.41*
CLz/F	L/h/kg	27.67 ± 1.09	23.64 ± 1.35*	17.59 ± 2.37**
Vz/F	L/kg	53.25 ± 3.64	48.95 ± 21.13	34.80 ± 6.57**
C_max	ng/mL	332.00 ± 52.79	396.05 ± 37.19*	494.51 ± 130.68**

Group A: the control group (0.5% CMC-Na), Group B: 20 mg/kg isavuconazole and Group C: 20 mg/kg fluconazole. (n = 6, mean ± SD). Compared with Group A, *P < 0.05, **P < 0.01

ISSN: 2661-801X